Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2a proof of concept (POC), open-label, multicenter trial evaluating the safety, pharmacokinetics and anti-tumor efficacy of PRP in patients with patients with advanced epithelial ovarian cancer who have failed prior anti-cancer therapy regimen

X
Trial Profile

A Phase 2a proof of concept (POC), open-label, multicenter trial evaluating the safety, pharmacokinetics and anti-tumor efficacy of PRP in patients with patients with advanced epithelial ovarian cancer who have failed prior anti-cancer therapy regimen

Status: Planning
Phase of Trial: Phase II

Latest Information Update: 22 Jan 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Chymotrypsinogen/trypsinogen (Primary)
  • Indications Ovarian cancer
  • Focus Proof of concept; Therapeutic Use
  • Sponsors Propanc Biopharma
  • Most Recent Events

    • 22 Jan 2021 New trial record
    • 18 Jan 2021 According to a Propanc Biopharma media release, the company looks forward to a potential collaboration with the clinical trial investigator Dr Fernando Galvez Montosa from the University Hospital of Jaen, in Granada, Spain, for this study.
    • 18 Jan 2021 According to a Propanc Biopharma media release, this study is planned to begin shortly after the completion of Phase 1b FIH study. This study is hoped to finalized in 2021.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top